Cytek Biosciences, Inc.

NASDAQ:CTKB

Medical - Devices

Healthcare
$5.92 -2.64%

-$0.11 today

Market cap
$774.24M
Beta
1.19
P/E (TTM)
-6.7
EPS (TTM)
-$0.57
52W Low $2.90High $6.18

Volume 1.05M

Average 0.88M

CTKB Pre-Tax Margin

Income before tax as a percentage of revenue.

Cytek Biosciences, Inc.NASDAQ: CTKB

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -39.4%

Pre-tax margin was -39.4% in Q1 FY2026, down 12.2 pp from a year earlier. On a trailing-twelve-month basis it was -17.6%, down 13.6 pp year over year. Over 3 fiscal years it narrowed by 15.6 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-39.4%-32.9 pp QoQ
Last fiscal yearDec 2025
-14.8%-12.0 pp YoY
LTMMar 2026
-17.6%-13.6 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-12.2 pp——
1 year-12.0 pp——
3 years-15.6 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-14.8%
Year-over-year change
-12.0pp

Pre-Tax Margin vs competitors

How CTKB compares with its peers on the latest reported figures

  • CTKB's LTM Mar 2026 pre-tax margin of -17.6% is the 5th highest of the 6 companies compared; the peer median is -0.8%.
  • Its year-over-year change of -13.6 pp is the 5th highest of 6, against a peer median of -4.1 pp.
  • Over three fiscal years its change of -15.6 pp compares with a peer median of +25.2 pp.
CTKB Competitors Peer median
Pre-Tax Margin for CTKB and competitors
Company Period LTM level YoY 3-year change
AAgilent Technologies, Inc.LTM Jul 202622.5% +2.0 pp-1.3 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202613.5% -4.1 pp+206.4 pp
BRKRBruker CorporationLTM Jun 2026-0.8% -4.8 pp-15.8 pp
TXG10x Genomics, Inc.LTM Sep 2026-10.5% +0.9 pp+25.2 pp
CTKBCytek Biosciences, Inc.LTM Mar 2026-17.6% -13.6 pp-15.6 pp
LABStandard BioTools Inc.LTM Mar 2026-101.8% -20.3 pp+83.6 pp
Peer median (excluding CTKB) -0.8%-4.1 pp+25.2 pp

Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue127.95M164.04M193.02M200.45M201.49M
Cost of Revenue48.81M63.06M83.59M89.35M97.03M
Gross Profit79.14M100.97M109.43M111.11M104.46M
Gross Margin61.9%61.6%56.7%55.4%51.8%
Research & Development24.44M34.86M44.15M39.4M36.47M
Selling, General & Admin45.55M67.92M93.12M92.23M108.38M
Operating Expenses69.99M102.78M137.27M131.63M144.84M
Depreciation & Amortization1.24M5.66M9.23M10.49M11.98M
EBITDA8.92M9.49M(4.41M)4.79M(17.39M)
EBITDA Margin7.0%5.8%-2.3%2.4%-8.6%
Operating Income9.16M(1.8M)(27.85M)(20.52M)(40.38M)
Operating Margin7.2%-1.1%-14.4%-10.2%-20.0%
Interest Income49K4.62M6.41M10.36M2.22M
Interest Expense1.74M2.57M2.07M0474K
Other Income / Expenses(3.22M)3.06M12.14M14.82M10.54M
Income Before Tax5.94M1.26M(15.71M)(5.7M)(29.84M)
Pre-Tax Margin4.6%0.8%-8.1%-2.8%-14.8%
Income Tax Expense2.91M(1.22M)(3.56M)320K36.7M
Net Income3M2.58M(12.15M)(6.02M)(66.54M)
Net Margin2.3%1.6%-6.3%-3.0%-33.0%
EPS (Basic)0.030.02(0.09)(0.05)(0.52)
EPS (Diluted)0.030.02(0.09)(0.05)(0.52)
Weighted Avg Shares133.75M134.51M135.28M130.61M127.75M
Weighted Avg Shares (Diluted)133.75M138.56M135.28M130.61M127.75M

Cytek Biosciences, Inc.

NASDAQ:CTKB

Intrinsic Alpha fair value

Locked

Current Price

$5.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.